References
- Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–80.10.1093/jac/dki248
- Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66(9):1963–71.10.1093/jac/dkr242
- CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004. Am J Infect Control. 2004;32(8):470–85.
- Jin G-M, Dong Y-M, Yu A-R, Zhang Q-L. A meta-analysis of epidemiology of intracranial infection after craniotomy. Chin J Clin Neurosurg. 2007;12(3):149–51.
- Lengerke C, Haap M, Mayer F, Kanz L, Kinzig M, Schumacher U, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother. 2011;55(1):449–50.10.1128/AAC.00635-10
- Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentration of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9.
- Chen G-Q, Wang Q, Shi Z-H, Xv M, Chen K, Chen L, et al. Study of concentration of vancomycin in serum and cerebrospinal fluid during continuous intravenous infusion. Chin Med J. 2010;32(6):450–3.
- Chen K, Wu Y-X, Wang Q, Wang J-Q, Li X-G, Zhao Z-G, et al. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. J Crit Care. 2015; 30(1):218.e1-5.10.1016/j.jcrc.2014.09.020
- Kell CA, Hunfeld KP, Wagner S, Nern C, Seifert V, Brodt HR, et al. Chronic meningoencephalomyelitis due to Mycobacterium fortuitum in an immunocompetent patient. J Neurol. 2008;255(11):1847–9.10.1007/s00415-008-0056-y
- Dandache P, Nicolar DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumonia meningitis. Infect Dis Clin Pract. 2009;17(1):66–8.10.1097/IPC.0b013e318181fa38
- Wadi JA, Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tegecycline. Ann Saudi Med. 2008;27(6):456–8.
- EdizTutuncu E, Kuscu F, Gurbuz Y, Ozturk B, Haykir A, Sencan I. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis. 2010;14(3):e224-6.
- Huang CR, Chen SF, Lu CH, Chuang YC, Tsai NW, Chang CC, et al. Clinical characteristics and therapeutic outcomes of nosocomial super-infection in adult bacterial meningitis. BMC Infect Dis. 2011;11:133. doi:10.1186/1471-2334-11-133
- Chen J, Orsini J, Killu C. Poor central nervous system penetration of tigecycline in a patient with sepsis and ventriculitis caused by multidrug-resistant Klebsiella pneumonia. J Pharm Technol. 2007;23(6):344–8.
- Tak V, Mathur P, Varghese P, Misra MC. Elizabethkingia meningoseptica: an emerging pathogen causing meningitis in ahospitalized adult trauma patient. Indian J Med Microbiol. 2013;31(3):293–5.
- Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rimas part of the tigecycline evaluation and surveillance trial (TEST). Int J Antimicrob Agents. 2009;33(2):130–6.10.1016/j.ijantimicag.2008.07.031